Shots:

• Novo Nordisk to acquire in all-cash transaction- making a total deal value ~$2.1B which included $725M as upfront and a remaining as regulatory and sales milestones
• The acquisition of Corvidia Therapeutics along with its lead candidate- ziltivekimab allow the Novo Nordisk to expand its footprints across cardiometabolic diseases
• Ziltivekimab is a fully human mAb targeting IL-6- is being evaluated P-IIb RESCUE study to reduce the risk of MACE in CKD patients with ASCVD and inflammation. AstraZeneca had acquired Corvidia for $443M in 2013 and spun out it in 2015

Click here to read full press release/ article 

Ref: Novo Nordisk | Image: Corvidia